Table 2.
CAR-NK cell clinical trials.
| No. | NCT | Start Year | Stage | Tumors | Target | NK source | sponsor locations | CAR structure | Gene transfer |
|---|---|---|---|---|---|---|---|---|---|
| Trials completed | |||||||||
| 1 | NCT00995137 | 2009 | I | B-ALL | CD19 | PB-NK | St. Jude Children's Research Hospital, US | ScFv-CD8αTM-CD137-CD3ζ | mRNA electroporation |
| 2 | NCT02944162 | 2016 | I/II | AML | CD33 | NK92 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | ScFv-CD28-CD137-CD3ζ | LV* |
| Trials actively recruiting | |||||||||
| 1 | NCT01974479 | 2013 | II | B-ALL | CD19 | PB-NK | National University Health System, Singapore | ScFv-CD8αTM-CD137-CD3ζ | mRNA electroporation |
| 2 | NCT02742727 | 2016 | I/II | Lymphoma, leukaemia | CD7 | NK92 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | ScFv-CD28-CD137-CD3ζ | electroporation |
| 3 | NCT02839954 | 2016 | I/II | Solid tumour | MUCI | NK92 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | ScFv-CD28-CD137-CD3ζ | LV |
| 4 | NCT02892695 | 2016 | I/II | Lymphoma, leukaemia | CD19 | NK92 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., China | ScFv-CD28-CD137-CD3ζ | LV |
| 5 | NCT03056339 | 2017 | I/II | B-lymphoma | CD19 | UCB-NK | MD Anderson, US | iCasp9-ScFv-CD28-CD3ζ-IL-15 | RV⁎⁎ |
| 6 | NCT03383978 | 2017 | I | GBM | HER2 | NK92 | Johann Wolfgang Goethe University Hospital, Germany | ScFv-CD28-CD3ζ | LV |
| 7 | NCT03415100 | 2018 | I | Metastatic solid tumour | NKG2DL | PB-NK | The Third Affiliated Hospital of Guangzhou Medical University, China | ScFv-CD8αTM-CD3ζ; ScFv-CD8αTM-DAP12 | mRNA electroporation |
| 8 | NCT03656705 | 2018 | I | NSCLC | NR | NK92 | Xinxiang medical university, China | NR | RV/LV |
| 9 | NCT03940833 | 2019 | I/II | R/R multiple myeloma | BCMA | NK92 | Asclepius Technology Company Group (Suzhou) Co., Ltd., China | NR | LV |
| 10 | NCT03941457 | 2019 | I/II | Pancreatic Cancer | ROBO1 | NK92 | Asclepius Technology Company Group (Suzhou) Co., Ltd., China | NR | LV |
| 11 | NCT03940820 | 2019 | I/II | Solid tumour | ROBO1 | NK92 | Asclepius Technology Company Group (Suzhou) Co., Ltd., China | NR | LV |
| 12 | NCT04245722 | 2020 | I | B-cell lymphoma, CLL | CD19 | iPSC (FT596) | Fate Therapeutics, San Diego, USA | scFv-NKG2D-2B4-CD3ζ-IL-15/R-hnCD16 | LV |
| Trials not yet recruiting | |||||||||
| 1 | NCT03692767 | Early I | Refractory B-cell lymphoma | CD22 | Unknown | Allife Medical Science and Technology, Beijing, China | |||
| 2 | NCT03690310 | Early I | Refractory B-cell lymphoma | CD19 | Unknown | Allife Medical Science and Technology, Beijing, China | |||
| 3 | NCT03692637 | Early I | Epithelial ovarian cancer | Mesothelin | PB-NK | Allife Medical Science and Technology, Beijing, China | |||
| 4 | NCT03692663 | Early I | Castration-resistant prostate Cancer | PSMA | Unknown | Allife Medical Science and Technology, Beijing, China | |||
| 5 | NCT03824964 | Early I | Refractory B-cell lymphoma | CD19/CD22 | Unknown | Beijing Cancer Hospital, Beijing, China | |||
⁎
LV: lentivirus
⁎⁎
RV: retrovirus